Industry top-down
Drug Manufacturers - Specialty & Generic
Latest reported revenue & EPS across the covered companies in this industry, with year-over-year (YoY) change. From disclosed earnings — not investment advice.
AI industry top-down
In the specialty and generic pharmaceutical industry, company performance varied significantly in Q1 FY2026. While some firms achieved strong double-digit revenue growth, others reported revenue declines. Earnings Per Share (EPS) also showed substantial fluctuations across companies, indicating a mixed trend. The industry's overall median revenue growth stood at approximately 5%.
- Significant disparity in sales growth rates by company (up to 110% increase, up to 12% decrease)
- Mixed performance in Earnings Per Share (EPS) growth/decline rates (up to 116% increase, up to 80% decrease)
- The industry median sales growth rate is approximately 5%
AI synthesis of disclosed results and analyst research across these companies — not investment advice.
Companies — latest quarter
| Company | Period | Revenue | Rev YoY | EPS | EPS YoY | Surprise |
|---|---|---|---|---|---|---|
| TEVATEVA PHARMACEUTICAL INDUSTRIES LTD | FY2026 Q2 | $4.14B | -0.8% | $-0.49 | — | — |
| TEVJFTEVA PHARMACEUTICAL INDUSTRIES LTD | FY2026 Q2 | $4.14B | -0.8% | $-0.49 | — | — |
| ZTSZoetis Inc. | FY2026 Q2 | $2.47B | +0.3% | $1.65 | +2.5% | — |
| VTRSViatris Inc | FY2026 Q2 | $3.75B | +5.0% | $-0.10 | — | — |
| UTHRUNITED THERAPEUTICS Corp | FY2026 Q2 | $783.3M | -1.9% | $7.27 | +13.4% | — |
| NBIXNEUROCRINE BIOSCIENCES INC | FY2026 Q2 | $959M | +39.5% | $1.39 | +31.1% | — |
| ELANElanco Animal Health Inc | FY2026 Q2 | $1.37B | +10.2% | $0.11 | — | — |
| AMRXAmneal Pharmaceuticals, Inc. | FY2026 Q2 | $796.2M | +9.9% | $0.18 | +157.1% | — |
| HIMSHims & Hers Health, Inc. | FY2026 Q2 | $753.21M | +38.2% | $-0.37 | — | — |
| ALKSAlkermes plc. | FY2026 Q2 | $496.01M | +27.0% | $0.00 | -100.0% | — |
| LNTHLantheus Holdings, Inc. | FY2026 Q2 | $388.18M | +2.7% | $1.11 | -0.9% | — |
| LQDALiquidia Corp | FY2026 Q2 | $171.68M | — | $0.74 | — | — |
| KNSAKiniksa Pharmaceuticals International, plc | FY2026 Q1 | $214.27M | +55.5% | $0.27 | +145.5% | — |
| 128940Hanmi Pharm. Co., Ltd. | FY2026 Q2 | ₩467.25B | +29.3% | ₩6566.00 | +115.1% | — |
| INDVIndivior Pharmaceuticals, Inc. | FY2026 Q2 | $343M | +13.6% | $0.98 | — | — |
| 000100YUHAN CORPORATION | FY2026 Q2 | ₩639.45B | — | ₩940.00 | — | — |
| AMLXAmylyx Pharmaceuticals, Inc. | FY2025 Q3 | $0 | -100.0% | $-0.37 | — | — |
| CURLFCuraleaf Holdings, Inc. | FY2026 Q2 | $340.1M | — | $0.05 | — | — |
| SUPNSUPERNUS PHARMACEUTICALS, INC. | FY2026 Q2 | $219.06M | +32.4% | $-1.01 | — | — |
| TRLVTrulieve Cannabis Corp. | FY2025 Q1 | $297.76M | +0.0% | $-0.16 | — | — |
| PBHPrestige Consumer Healthcare Inc. | FY2027 Q1 | $265.71M | +6.5% | $0.61 | -35.8% | — |
YoY = vs. the same quarter last year · Surprise = EPS actual vs. consensus. Latest reported quarter per company, from disclosed earnings filings. QoQ is omitted because quarterly filings don’t break out Q4 (US) and report cumulatively (KR).